Last viewed:
CDAK
Prices are updated after-hours
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
(0.0% 1d)
(0.0% 1m)
(0.0% 1y)
(0.0% 2d)
(0.0% 3d)
(0.0% 7d)
(-0.9%
volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 2,099,289
http://www.codiakbio.com
Sec
Filling
|
Patents
| 105 employees
(United States) Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. The company was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA.
diagnostics
add to watch list
Paper trade
email alert is off
Press-releases
Delisting of Securities of Pingtan Marine Enterprise Ltd.; SRAX, Inc.; SVB Financial Group; Signature Bank; Codiak BioSciences, Inc.; PLx Pharma Inc.; Virgin Orbit Holdings, Inc.; Kalera Public Limited Company; Pear Therapeutics, Inc.; and Intelligent Medicine Acquisition Corp. from The Nasdaq Stock Market
Published: 2023-04-28
(Crawled : 21:00)
- globenewswire.com
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| Email alert
Add to watchlist
NDAQ
|
$60.01
-0.03%
-0.03%
2.8M
|
Finance
| Email alert
Add to watchlist
PME
|
$0.27
0.0%
0
|
Miscellaneous
| Email alert
Add to watchlist
PLXP
|
$0.087
-4.6%
50M
|
Health Technology
| Email alert
Add to watchlist
SBNY
4
d
|
$3.15
0.0%
150K
|
Finance
| Email alert
Add to watchlist
SRAX
|
$0.19
5.26%
600
|
Commercial Services
| Email alert
Add to watchlist
SIVB
|
$106.04
-171.55%
0
|
Finance
| Email alert
Add to watchlist
IQMD
|
$11.04
0.09%
220K
|
n/a
| Email alert
Add to watchlist
CDAKQ
|
$0.0016
487.5%
2.4M
|
n/a
| Email alert
Add to watchlist
VORBQ
|
$0.003
233.33%
41K
|
n/a
| Email alert
Add to watchlist
PEARQ
|
$0.0001
0.0%
34K
|
n/a
| Email alert
Add to watchlist
marine
pharma
kalera
acquisition
financial
market
Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process
Published: 2023-03-27
(Crawled : 13:00)
- biospace.com/
XYF
|
$3.79
-0.78%
0.0%
1K
|
Finance
| 30.82%
| O: -3.08%
H: 4.24%
C: 3.18%
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| -87.22%
| O: -64.05%
H: 59.08%
C: 18.84%
Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference
Published: 2022-11-28
(Crawled : 20:00)
- globenewswire.com
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| Email alert
Add to watchlist
conference
Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Published: 2022-11-10
(Crawled : 15:20)
- biospace.com/
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| -92.5%
| O: 2.04%
H: 9.65%
C: 5.78%
preclinical
immunotherapy
meeting
cancer
Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses
Published: 2022-10-12
(Crawled : 14:00)
- biospace.com/
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| -91.63%
| O: 3.48%
H: 0.0%
C: -4.78%
preclinical
vaccine
sars-cov-2
Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants
Published: 2022-09-13
(Crawled : 02:00)
- globenewswire.com
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| -96.75%
| O: -32.76%
H: 3.39%
C: -5.93%
offering
Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring
Published: 2022-08-30
(Crawled : 13:20)
- globenewswire.com
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| -97.39%
| O: 3.21%
H: 0.0%
C: 0.0%
program
Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022
Published: 2022-07-11
(Crawled : 14:00)
- globenewswire.com
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| -98.2%
| O: 0.95%
H: 0.94%
C: -5.94%
conference
biotech
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine
Published: 2022-07-05
(Crawled : 11:00)
- globenewswire.com
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| -98.01%
| O: -10.14%
H: 14.4%
C: 12.06%
vaccine
Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™
Published: 2022-06-30
(Crawled : 11:00)
- globenewswire.com
CDAK
|
$0.057
-55.99%
-131.25%
0
|
Health Technology
| -98.41%
| O: -0.84%
H: 0.0%
C: -18.87%
il-12
trials
update
phase 1
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0000950170-23-011055
4
2023-03-30
2023-03-30
Sell
S
1628
7458
0000950170-23-011036
4
2023-03-30
2023-03-29
Sell
S
11762
0
0000950170-23-011029
4
2023-03-30
2023-03-28
Sell
S
1932
0
0000950170-23-011029
4
2023-03-30
2023-03-28
Sell
S
7432
1932
0000950170-23-011028
4
2023-03-30
2023-03-28
Sell
S
13412
0